Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …

Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer
(TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy …

Background Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer
mortality but may increase mortality from other causes. Information regarding treatment …

Cisplatin (DDP) was reported to improve pathological complete response (pCR) rates in
triple-negative breast cancer (TNBC) patients, however, the molecular mechanism still …

Simple Summary Triple negative breast cancer (TNBC) represents 15 to 20% of all breast
cancers in the United States. The main treatment option remains chemotherapy, despite …

Mortality from breast cancer is almost exclusively a result of tumor metastasis and resistance
to therapy and therefore understanding the underlying mechanisms is an urgent challenge …

As the field of translational 'omics has progressed, refined classifiers at both genomic and
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …

Highlights•Breast cancer in young women should be treated based on stage and biology of
disease.•Management of breast cancer in young women requires special considerations …